Literature DB >> 28760370

What NMR can do in the biopharmaceutical industry.

Róbert Kiss1, Ádám Fizil2, Csaba Szántay3.   

Abstract

Nuclear magnetic resonance (NMR) spectroscopy has a unique capability to probe the primary and higher order molecular structure and the structural dynamics of biomolecules at an atomic resolution, and this capability has been greatly fortified over the last five decades by an astonishing NMR instrumental and methodological development. Because of these factors, NMR has become a primary tool for the structure investigation of biomolecules, spawning a whole scientific subfield dedicated to the subject. This role of NMR is by now well established and broadly appreciated, especially in the context of academic research dealing with proteins that are purified and isotope-labeled in order to facilitate the necessary sophisticated multidimensional NMR measurements. However, the more recent industrial development, manufacturing, and quality control of biopharmaceuticals provide a different framework for NMR. For example, protein drug substances are not isotope-labeled and are present in a medium of excipients, which make structural NMR measurements much more difficult. On the other hand, biotechnology involves many other analytical requirements that can be efficiently addressed by NMR. In this respect the scope and limitations of NMR are less well understood. Having the non-expert reader in mind, herein we wish to highlight the ways in which modern NMR can effectively support biotechnological developments. Our focus will be on biosimilar proteins, pointing out certain cases where its use is probably essential. Based partly on literature data, and partly on our own hands-on experience, this paper is intended to be a guide for choosing the proper NMR approach for analytical questions concerning the structural comparability of therapeutic proteins, monitoring technology-related impurities, protein quantification, analysis of spent media, identification of extractable and leachable components, etc. Also, we focus on critical considerations, particularly those coming from drug authority guidelines, which limit the use of the well-established NMR tools in everyday practice.
Copyright © 2017 Elsevier B.V. All rights reserved.

Keywords:  Bioanalytics; Biopharmaceutics; Biosimilarity; Higher order structure; NMR; Therapeutic proteins

Mesh:

Substances:

Year:  2017        PMID: 28760370     DOI: 10.1016/j.jpba.2017.07.004

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  2D J-correlated proton NMR experiments for structural fingerprinting of biotherapeutics.

Authors:  Robert G Brinson; John P Marino
Journal:  J Magn Reson       Date:  2019-08-20       Impact factor: 2.229

2.  Platform development for expression and purification of stable isotope labeled monoclonal antibodies in Escherichia coli.

Authors:  Prasad T Reddy; Robert G Brinson; J Todd Hoopes; Colleen McClung; Na Ke; Lila Kashi; Mehmet Berkmen; Zvi Kelman
Journal:  MAbs       Date:  2018-07-30       Impact factor: 5.857

3.  Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics.

Authors:  Robert G Brinson; John P Marino; Frank Delaglio; Luke W Arbogast; Ryan M Evans; Anthony Kearsley; Geneviève Gingras; Houman Ghasriani; Yves Aubin; Gregory K Pierens; Xinying Jia; Mehdi Mobli; Hamish G Grant; David W Keizer; Kristian Schweimer; Jonas Ståhle; Göran Widmalm; Edward R Zartler; Chad W Lawrence; Patrick N Reardon; John R Cort; Ping Xu; Feng Ni; Saeko Yanaka; Koichi Kato; Stuart R Parnham; Desiree Tsao; Andreas Blomgren; Torgny Rundlöf; Nils Trieloff; Peter Schmieder; Alfred Ross; Ken Skidmore; Kang Chen; David Keire; Darón I Freedberg; Thea Suter-Stahel; Gerhard Wider; Gregor Ilc; Janez Plavec; Scott A Bradley; Donna M Baldisseri; Mauricio Luis Sforça; Ana Carolina de Mattos Zeri; Julie Yu Wei; Christina M Szabo; Carlos A Amezcua; John B Jordan; Mats Wikström
Journal:  MAbs       Date:  2018-12-22       Impact factor: 5.857

Review 4.  From Synthesis to Characterization of Site-Selective PEGylated Proteins.

Authors:  Lisandra Herrera Belén; Carlota de Oliveira Rangel-Yagui; Jorge F Beltrán Lissabet; Brian Effer; Manuel Lee-Estevez; Adalberto Pessoa; Rodrigo L Castillo; Jorge G Farías
Journal:  Front Pharmacol       Date:  2019-12-18       Impact factor: 5.810

5.  Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product.

Authors:  Piroska Kovács; Tamás Schäfer; Viktor Háda; Helga Hevér; Sonja Klingelhöfer; Merle Nebel; Tanja Stadie; Róbert Kiss; Zoltán Urbányi
Journal:  BioDrugs       Date:  2020-02       Impact factor: 5.807

6.  The transient expression of recombinant proteins in plant cell packs facilitates stable isotope labelling for NMR spectroscopy.

Authors:  Patrick Opdensteinen; Laura E Sperl; Mariam Mohamadi; Nicole Kündgen-Redding; Franz Hagn; Johannes Felix Buyel
Journal:  Plant Biotechnol J       Date:  2022-07-19       Impact factor: 13.263

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.